| Identification | Back Directory | [Name]
Buserelin | [CAS]
57982-77-1 | [Synonyms]
hoe766a
receptal
etilamide
ici123215
BUSERELIN
Buserilin
Suprefact
Buserelin CRS
BUSERELIN PH. EUR.
Buserelin, Buserelina
(d-ser(tbu)(sup6)-ea(sup10))-lhrh
d-ser-(tbu)(sup6)-lhrh-ethylamide
(DES-GLY10,D-SER(TBU)6,PRO-NHET9)-LHRH
PYR-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-NHET
P-GLU-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-NHET
d-ser(tbu(sup6))-lh-rh-(1-9)-nonapeptideethylamide
(d-ser(bu(supt)(sup6)))-lh-rh(1-9)nonapeptide-ethylamide
Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt acetate salt
(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormon
(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormone
luteinizinghormone-releasinghormone(pig),6-(o-(1,1-dimethylethyl)-d-serine)
1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-
(Des-Gly10,D-Ser(tBu)6,Pro-NHEt 9)-LHRH acetate salt Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt acetate salt
BuserelinQ: What is
Buserelin Q: What is the CAS Number of
Buserelin Q: What is the storage condition of
Buserelin
Buserilin,1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)-1-pyrrolidinyl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide | [EINECS(EC#)]
261-061-9 | [Molecular Formula]
C60H86N16O13 | [MDL Number]
MFCD00870371 | [MOL File]
57982-77-1.mol | [Molecular Weight]
1239.42 |
| Chemical Properties | Back Directory | [Appearance]
White or slightly yellowish powder, hygroscopic. | [alpha ]
D20 -40.4° (c = 1 in dimethylacetamide) | [Boiling point ]
845.19°C (rough estimate) | [density ]
1.0711 (rough estimate) | [refractive index ]
1.6200 (estimate) | [solubility ]
Sparingly soluble in water and in dilute acids. | [form ]
Solid | [pka]
9.82±0.15(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
CUWODFFVMXJOKD-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
White or slightly yellowish powder, hygroscopic. | [Uses]
Gonad-stimulating principle. | [Brand name]
Suprefact
(Hoechst-Roussel). | [Description]
Buserelin (Suprefact?) is a hormonal therapy drug used to treat advanced prostate cancer. It is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. | [Definition]
ChEBI: Buserelin is an oligopeptide. | [Clinical Use]
Treatment of advanced prostate cancer and
endometriosis
Pituitary desensitisation in preparation for ovulation
induction regimens using gonadotrophins | [Side effects]
Using too much Buserelin Injection may make you feel weak, nervous, dizzy and sick. You may also have a headache, hot flushes, stomach pain, swelling of the legs and breast pain. You may also have pain, bleeding or hardening of the skin at the site of injection | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Metabolic inactivation by peptides occurs in the liver
and kidney. The drug is also inactivated by pituitary
membrane enzymes.
Excreted in the urine and bile as unchanged drug and
metabolites. |
|
|